The importance of the quadrivalent HPV vaccine in the elimination of cervical cancer in Brazil - Revista Brasileira de Ginecologia e Obstetrícia
Revista Brasileira de Ginecologia e Obstetrícia. 2024;46:e-rbgoedt4
The introduction of the quadrivalent HPV vaccine Gardasil 4V into the Brazilian National Immunization Schedule was approved by the National Committee for Technology Incorporation into the Unified Health System (Conitec) and incorporated into the National Immunization Schedule in 2014. This decision was based on a previous cost-effectiveness study that analyzed different scenarios for its introduction and on a favorable recommendation issued by the Technical Advisory Committee of the National Immunization Program (PNI). A partnership for technology transfer was established between the national laboratory Butantan and the laboratory Merck Sharp & Dohme to ensure the sustainability of the HPV vaccine.
The vaccination strategy was initiated in March 2014 with the target population of girls aged 11-13 years and the priority vaccination location in public and private schools for the first dose (D1), with guidance for completing the vaccination schedule at Basic Health Units. The vaccination coverage target established was 90% with a vaccination schedule using three doses (first dose, second dose six months later and third dose 60 months after the first dose). In 2016, prior to the administration of the third dose in any age group, the schedule was changed to two doses in view of the publication of new studies showing no differences in antibody production between the two-dose and three-dose vaccination schedules.
[…]
Search
Search in:
Search
Search in:
The introduction of the quadrivalent HPV vaccine Gardasil 4V into the Brazilian National Immunization Schedule was approved by the National Committee for Technology Incorporation into the Unified Health System (Conitec) and incorporated into the National Immunization Schedule in 2014. This decision was based on a previous cost-effectiveness study that analyzed different scenarios for its introduction and on a favorable recommendation issued by the Technical Advisory Committee of the National Immunization Program (PNI). A partnership for technology transfer was established between the national laboratory Butantan and the laboratory Merck Sharp & Dohme to ensure the sustainability of the HPV vaccine.
The vaccination strategy was initiated in March 2014 with the target population of girls aged 11-13 years and the priority vaccination location in public and private schools for the first dose (D1), with guidance for completing the vaccination schedule at Basic Health Units. The vaccination coverage target established was 90% with a vaccination schedule using three doses (first dose, second dose six months later and third dose 60 months after the first dose). In 2016, prior to the administration of the third dose in any age group, the schedule was changed to two doses in view of the publication of new studies showing no differences in antibody production between the two-dose and three-dose vaccination schedules.
[...]
Comments